COMMUNIQUÉS West-GlobeNewswire

Interim Report Q3 2025: Solid quarter with 1% organic growth, 11% EBITA margin and DKK 410 million cash flow
06/11/2025
Highlights The Hearing division delivered 7% organic revenue growth driven by the continued strong performance of ReSound Vivia, enabling broad-based market share gains. The divisional profit margin ended at 34%, driven [...]
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
06/11/2025
Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024 RUCONEST® third quarter revenu e increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting [...]
BioVersys Announces First Subjects Dosed in Phase 1 Clinical Trial of Bv100 in China
06/11/2025
Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) -- First healthy volunteer dosed with BV100 in China in mandatory Phase 1 trial Inclusion of Chinese clinical sites by H2 [...]
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
06/11/2025
HAYWARD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines [...]
BillionToOne Announces Pricing of Upsized Initial Public Offering
06/11/2025
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced [...]
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
06/11/2025
SUNNYVALE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
05/11/2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings [...]
Tarsus to Participate in Upcoming Investor Conference
05/11/2025
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2 nd Annual Healthcare Innovation [...]
Benitec Biopharma Inc. Announces Proposed Public Offering
05/11/2025
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines [...]
Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
05/11/2025
Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss only Body mass index (BMI) and waist-to-height ratio (a measurement of [...]
STERIS Announces Financial Results for Fiscal 2026 Second Quarter
05/11/2025
Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9% As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47 Fiscal 2026 constant [...]
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
05/11/2025
MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]
PharmaCorp Announces C$15 Million Bought Deal Public Offering
05/11/2025
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE [...]
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
05/11/2025
SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s [...]
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
05/11/2025
-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash [...]
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
05/11/2025
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 [...]
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
05/11/2025
- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. [...]
The Pennant Group Announces Expansion of Credit Facility
05/11/2025
EAGLE, Idaho, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced that the [...]
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
05/11/2025
Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 [...]

Pages